Global life sciences venture capital funding has reverted to its pre-pandemic long-term trend. Peak pandemic funding and initial public offering activity in 2020 and 2021 resulted in the creation of many new life sciences companies. Some of these companies faced several hurdles in 2023, including a challenging fundraising environment, higher interest rates and economic uncertainty. Heading into 2024, some of this uncertainty will likely remain, however, companies are now adept at navigating a more challenging landscape. Developing strategies to operate lean in a capital-constrained environment will continue to be an important tool in 2024, as investors remain cautious with their allocations.
Life Sciences Funding in View
Sandy Romero • 1/29/2024
U.S. Life Sciences Funding – Breakdown by Market
Explore top U.S. life sciences markets on the map below. Click to view market level breakdowns of VC funding (and YoY change), number of deals, average deal size (and YoY change) and that market’s % of total U.S. funding.
WHATS NEXT FOR LIFE SCIENCES to LIFE SCIENCES INSIGHTS
Get the latest in Cushman & Wakefield Life Sciences research and commentary.
Subscribe
Related Insights
Research
Life Sciences Fit Out Cost Guide
Our 2025 Life Sciences Fit Out Cost Guide covers five lab types, two cGMP types, warehouse and office across the six major U.S. life sciences markets.
Brian Ungles • 11/1/2024
Research
Cushman & Wakefield’s 2024 life sciences market report covers national trends and dive deep into top global life sciences markets, for an in-depth look at this quickly changing industry.
Sandy Romero • 9/17/2024
Article
Life Science Update: Finding Talent and Fostering New Ideas
Encouraging collaboration to formulate new ideas and creating access to skilled talent remain priorities for life sciences companies. Among current life science industry trends, there are several hot locations for the life sciences, as well as a focus on amenities that spark ‘spontaneous interactions’.
Rachel Park • 10/19/2022